PRKCB and glioblastoma: Additionally, the methylation status of PRKCB was revealed as a potential novel biomarker for patient survival, and lastly, we found that the treatment with chemotherapeutic agents prior to radiotherapy can have a significant impact on the survival of the patients, which could lead to major improvements in clinical management and therapeutic approaches for GBM patients.